A new study reveals that ensifentrine, a novel COPD treatment, significantly reduces COPD-related healthcare usage over 48 ...

American Thoracic Society guidelines recommend that people with moderate or severe COPD who experience shortness of breath and/or exercise intolerance receive a combination of two different types of ...

This includes steroid-containing combinations and long-acting bronchodilators ... should be the foundation treatment for the majority of symptomatic COPD patients. In the CRYSTAL study, patients ...

Ohtuvayre™ (ensifentrine) launch recorded Q3 net sales of $5.6 million and October net sales exceeded Q3Through October more than 2,200 unique ...

CNS stimulants are a type of medication that can help with low energy and concentration caused by sleep disruptions from sleep apnea. Methylxanthine bronchodilators are muscle relaxers that make ...

Supported by regular phone calls or other contact to ensure that necessary medications and the like are adhered to, individualized management plans can result in better quality of life and fewer ...

UK-based Verona Pharma has scored a key win in a phase 3 trial of its chronic obstructive pulmonary disease (COPD) drug ensifentrine ... and is thought to combine bronchodilator and anti ...

Ohtuvayre™ (ensifentrine) is the Company’s first commercial product and the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti ...

This broad utilization across all patient types is consistent with market research and supports our belief that Ohtuvayre’s bronchodilator ... for COPD patients and can re-define the treatment ...

but it can be managed and treated by working with your healthcare team to develop a plan to keep your COPD under control. Along with quitting smoking, staying up to date with vaccinations, following ...

Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Verona Pharma (VRNA – Research Report), boosting the price target to ...